Ovid Therapeutics(NASDAQ) OVID

Ovid Therapeutics Inc. makes medicines for people with brain disorders. These drugs help patients manage seizures and other neurological issues. The company focuses on creating treatments for rare conditions.

Targeting Rare Brain Disorders

• OV329: Enzyme inhibitor targeting chemical pathways to manage seizures in specific rare disorders.
• OV101: Therapeutic candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome.
• KCC2 Activators: Portfolio of small molecules designed to treat drug-resistant seizures and brain conditions.

Strategic Funding and Partnerships

• Completed a private placement in October 2025 that raised $75.1 million.
• Secured $56.2 million through a private placement in March 2026.
• Formed research partnerships with AstraZeneca and Marinus Pharmaceuticals to advance its pipeline.

What Makes the Science Unique

Ovid is the only company holding a portfolio of direct potassium-chloride cotransporter 2 activators. Its team uses expertise in molecular pathways to create new treatments for neurological disorders.

Key Financial Statistics

• Revenue was $0.7 million for the six-month period ended June 30, 2026.
• Research and development expenses reached $21.1 million for the six-month period ended June 30, 2026, up $8.0 million year over year.
• Net loss was $32.0 million for the six-month period ended June 30, 2026.
• Cash and marketable securities totaled $169.8 million as of June 30, 2026.

Bottom Line

Ovid has evolved from a startup into a clinical-stage developer with a pipeline of specialized brain medicines. Its growth is supported by significant capital raises and partnerships with established pharmaceutical companies.